{"id":58509,"date":"2023-12-01T19:01:39","date_gmt":"2023-12-01T18:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/"},"modified":"2023-12-01T19:01:39","modified_gmt":"2023-12-01T18:01:39","slug":"psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/","title":{"rendered":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\nPsychoGenics is planning the development of RO7117997 for the treatment of multiple CNS conditions starting with sleep and seizure disorders<\/p>\n<p>PARAMUS, N.J.&#8211;(BUSINESS WIRE)&#8211;PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997, is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using the PsychoGenics\u2019 AI-enabled phenotypic screening platforms. PsychoGenics intends to evaluate RO7117997 as a potential treatment for several psychiatric and neurological conditions, starting with sleep and seizure disorders.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/5\/PsychoGenics_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/21\/PsychoGenics_Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/5\/PsychoGenics_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/22\/PsychoGenics_Logo.jpg\"><\/a><\/p>\n<p>\n&#8220;RO7117997 was originally identified through our partnership with Roche, employing our SmartCube\u00ae platform, and subsequent research at Roche revealed it to act as an ENT1 inhibitor,&#8221; stated Emer Leahy, PhD, President and CEO, PsychoGenics. &#8220;It is particularly gratifying that we have the opportunity to advance another phenotypically discovered drug candidate. Inhibition of ENT1 represents a novel approach for addressing a range of neuropsychiatric disorders. This license agreement perfectly aligns with our strategic objective of developing improved treatments for severely disabling CNS conditions.&#8221;<\/p>\n<p>\n\u201cWe are excited to expand our pipeline and are optimistic about the potential of ENT1 inhibitors in addressing a diverse array of disorders, as indicated by pre-clinical data,\u201d said David Bleakman, PhD, President, Drug Discovery, PsychoGenics. \u201cRO7117997 has already demonstrated a compelling safety profile in non-clinical studies, and we are on track to submit an IND application and commence clinical trials in 2024.&#8221;<\/p>\n<p>\n<b>About ENT1 inhibition<\/b><\/p>\n<p>\nENT1 inhibitors block the activity of the ENT1 transporter. By doing so, they prevent the uptake of adenosine into cells, leading to an increase in the extracellular concentration of adenosine. An increase in adenosine levels can improve sleep quality and reduce the frequency and severity of seizures through activation of adenosine receptors. Other potential applications for an ENT1 inhibitor include the treatment of neuropsychiatric conditions such as schizophrenia and addiction, neurodegenerative disorders, pain and inflammation.<\/p>\n<p>\n<b>About PsychoGenics<\/b><\/p>\n<p>\nPsychoGenics Inc. and its discovery arm, PGI Drug Discovery LLC (collectively known as PsychoGenics), have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping. PsychoGenics\u2019 drug discovery platforms, SmartCube\u00ae, NeuroCube\u00ae, PhenoCube\u00ae and eCube\u00ae, have been used in shared-risk partnerships with major pharmaceutical companies, including Sunovion, Roche and Karuna, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. PsychoGenics\u2019 capabilities also include standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis and quantitative immunohistochemistry. In addition, the Company offers a variety of mouse models that support research in areas such as Huntington\u2019s disease, autism spectrum disorders, psychosis\/schizophrenia, depression, PTSD, Alzheimer\u2019s disease, Parkinson\u2019s disease, muscular dystrophy, ALS, seizure disorders and pain.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n215 College Road<br \/>\n<br \/>Paramus, NJ 07652<br \/>\n<br \/>Tel: (914) 406-8000<br \/>\n<br \/>Fax: (914) 406-8090<br \/>\n<br \/><b><span class=\"bwuline\"><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.psychogenics.com&amp;esheet=53864768&amp;newsitemid=20231201150468&amp;lan=en-US&amp;anchor=www.psychogenics.com&amp;index=1&amp;md5=0546a610a10394228d7cc7e241c78013\" rel=\"nofollow noopener\" shape=\"rect\">www.psychogenics.com<\/a><\/span><\/b><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>PsychoGenics is planning the development of RO7117997 for the treatment of multiple CNS conditions starting with sleep and seizure disorders PARAMUS, N.J.&#8211;(BUSINESS WIRE)&#8211;PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58509","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PsychoGenics is planning the development of RO7117997 for the treatment of multiple CNS conditions starting with sleep and seizure disorders PARAMUS, N.J.&#8211;(BUSINESS WIRE)&#8211;PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-01T18:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/21\/PsychoGenics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders\",\"datePublished\":\"2023-12-01T18:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/\"},\"wordCount\":479,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231201150468\\\/en\\\/1956622\\\/21\\\/PsychoGenics_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/\",\"name\":\"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231201150468\\\/en\\\/1956622\\\/21\\\/PsychoGenics_Logo.jpg\",\"datePublished\":\"2023-12-01T18:01:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231201150468\\\/en\\\/1956622\\\/21\\\/PsychoGenics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231201150468\\\/en\\\/1956622\\\/21\\\/PsychoGenics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/","og_locale":"en_US","og_type":"article","og_title":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders - Pharma Trend","og_description":"PsychoGenics is planning the development of RO7117997 for the treatment of multiple CNS conditions starting with sleep and seizure disorders PARAMUS, N.J.&#8211;(BUSINESS WIRE)&#8211;PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/","og_site_name":"Pharma Trend","article_published_time":"2023-12-01T18:01:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/21\/PsychoGenics_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders","datePublished":"2023-12-01T18:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/"},"wordCount":479,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/21\/PsychoGenics_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/","url":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/","name":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/21\/PsychoGenics_Logo.jpg","datePublished":"2023-12-01T18:01:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/21\/PsychoGenics_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231201150468\/en\/1956622\/21\/PsychoGenics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-announces-exclusive-global-license-for-an-ind-ready-ent1-inhibitor-for-the-treatment-of-neuropsychiatric-disorders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58509"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58509\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}